These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22945814)

  • 41. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.
    Trump DL; Payne H; Miller K; de Bono JS; Stephenson J; Burris HA; Nathan F; Taboada M; Morris T; Hubner A
    Prostate; 2011 Sep; 71(12):1264-75. PubMed ID: 21271613
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of abiraterone in the management of metastatic castration-resistant prostate cancer.
    Rawlinson A; Mohammed A; Beatty J; Bell R; Miller M
    Expert Rev Anticancer Ther; 2012 Apr; 12(4):429-37. PubMed ID: 22500680
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Castration-resistant prostate cancer: AUA Guideline.
    Cookson MS; Roth BJ; Dahm P; Engstrom C; Freedland SJ; Hussain M; Lin DW; Lowrance WT; Murad MH; Oh WK; Penson DF; Kibel AS
    J Urol; 2013 Aug; 190(2):429-38. PubMed ID: 23665272
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Managing advanced prostate cancer: the rapidly changing treatment landscape.
    Dreicer R
    Am J Manag Care; 2014 Dec; 20(12 Suppl):S282-9. PubMed ID: 25734964
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting the androgen receptor in metastatic castration-resistant prostate cancer.
    Aragon-Ching JB
    Future Oncol; 2014 Feb; 10(3):329-32. PubMed ID: 24559439
    [No Abstract]   [Full Text] [Related]  

  • 46. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.
    Mitsiades N
    Cancer Res; 2013 Aug; 73(15):4599-605. PubMed ID: 23887973
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Circulating tumour cells as surrogate biomarkers in castration-resistant prostate cancer trials.
    Bjartell A
    Eur Urol; 2011 Nov; 60(5):905-7. PubMed ID: 21871707
    [No Abstract]   [Full Text] [Related]  

  • 48. Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.
    Antonarakis ES; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):206-18. PubMed ID: 21577233
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Re: Ito et al. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel (Urology 2011;78:1131-1135).
    Kathpalia R; Mandal S; Sankhwar S
    Urology; 2012 Jun; 79(6):1414; author reply 1414-5. PubMed ID: 22656421
    [No Abstract]   [Full Text] [Related]  

  • 50. Novel therapies for the treatment of advanced prostate cancer.
    Clarke JM; Armstrong AJ
    Curr Treat Options Oncol; 2013 Mar; 14(1):109-26. PubMed ID: 23322116
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and STAMPEDE Studies.
    Small EJ
    Cancer Cell; 2017 Jul; 32(1):6-8. PubMed ID: 28697343
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimal therapy sequencing in metastatic castration-resistant prostate cancer.
    Abouharb S; Corn PG
    Curr Oncol Rep; 2013 Jun; 15(3):217-23. PubMed ID: 23568599
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bone-targeted Novel Cytotoxic Polybisphosphonate Conjugate in Castration-resistant Prostate Cancer: A Multicenter Phase 1 Study.
    Thellenberg-Karlsson C; Nyman C; Nilsson S; Blom R; Márquez M; Castellanos E; Holmberg AR
    Anticancer Res; 2016 Dec; 36(12):6499-6504. PubMed ID: 27919973
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Advances in advanced prostate cancer - the continuing journey.
    Payne H; Davda R; Jones R; Crabb S; Troup J; Hughes S
    BJU Int; 2016 Jul; 118(1):17-9. PubMed ID: 26456636
    [No Abstract]   [Full Text] [Related]  

  • 55. Docetaxel and beyond.
    Tombal B
    Eur Urol; 2007 May; 51(5):1159-61. PubMed ID: 17229518
    [No Abstract]   [Full Text] [Related]  

  • 56. 2-weekly versus 3-weekly docetaxel for prostate cancer.
    Nanus DM; Tagawa ST
    Lancet Oncol; 2013 Feb; 14(2):98-9. PubMed ID: 23294852
    [No Abstract]   [Full Text] [Related]  

  • 57. Docetaxel treatment in castration-resistant prostate cancer: the triad gene-drug-disease.
    Faucz FR
    J Clin Endocrinol Metab; 2011 Feb; 96(2):351-3. PubMed ID: 21296995
    [No Abstract]   [Full Text] [Related]  

  • 58. [Research and development of hormone-related anti-prostate cancer drugs-17, 20-lyase inhibitors for prostate cancer].
    Hara T
    Nihon Yakurigaku Zasshi; 2010 Oct; 136(4):192-7. PubMed ID: 20948153
    [No Abstract]   [Full Text] [Related]  

  • 59. Editorial: New Drug Targets for Treatment of Recurrent/Metastatic Prostate Cancer.
    Festuccia C; Negri-Cesi P; Gravina GL
    Curr Drug Targets; 2016; 17(3):254-6. PubMed ID: 26876024
    [No Abstract]   [Full Text] [Related]  

  • 60. SCH 13521 in the treatment of advanced carcinoma of the prostate.
    Stoliar B; Albert DJ
    J Urol; 1974 Jun; 111(6):803-7. PubMed ID: 4133890
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.